Genesis Biomed-backed PolyFIL Diagnostics plans EUR 300,000 seed round after EUR 50,000 investment

• Genesis Biomed-backed PolyFIL Diagnostics launched with a EUR 50,000 seed investment via GENESIS Tech Transfer Boost.
• PolyFIL is developing a flow cytometry blood test to detect colorectal polyps and cancer, aiming to reduce unnecessary colonoscopies.
• The venture plans to raise a EUR 300,000 seed round to fund quality systems, kit manufacturing, and regulatory engagement.
• GENESIS Tech Transfer Boost holds 5% of founding shares in PolyFIL; Hospital La Paz’s biomedical research foundation holds 5%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genesis Biomed SL published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.